The incidence of Alzheimer’s Disease (AD) has reached epidemic proportions. More than 5 million Americans currently live with AD. While deaths from cardiovascular disease have fallen 14% since 2000, deaths from AD have increased by 89%. The cost of AD is projected to rise from $226 billion per year in 2015 up to $1.1 trillion in 2050. Approximately two-thirds of AD patients are women, and the diagnosis is often preceded by mild cognitive impairment (MCI). It’s believed that most patients suffer from MCI for at least 10 years prior to diagnosis and that the frequent dismissal of their symptoms by physicians and family leads to their missing a reasonable treatment window.

A concerned group of healthcare practitioners have embarked on the first rigorous trial of a very promising protocol designed to halt the progression of cognitive decline. We are calling this endeavor ReCODE or the Reversal of Cognitive Decline study. In the ReCODE trial we will employ Dr. Dale Bredesen’s ReCode Functional Medicine approach to reversing mild cognitive impairment and early dementia. You may be familiar with his book, The End of Alzheimer’s, which has been widely read and well-received. Our goal is that at least 25 people will complete the 9-month trial.

Our approach is to design a program for each study patient depending on their individual history, symptoms and a large set of laboratory data including digestive function and microbiome, nutrient and hormonal status, cardiovascular assessment, infectious etiologies, mold and chemical toxins and advanced genetic analysis. The study protocol involves the subjects adopting a specific diet, committing to regular exercise and working to optimize sleep, as well as learning to employ stress reduction techniques. Each patient will also be treated with individualized supplements and prescriptions where indicated, as well as treatment of any of the known dementia contributors that are uncovered.

Here is the detailed description from clinicaltrials.gov

The objective of the study is to determine if the ReCODE treatment has a measurable impact on the typical progression of neurocognitive decline observed in patients with Alzheimer's Disease (AD) and patients who are exhibiting Mild Cognitive Impairment (MCI). MCI is often a precursor to an AD diagnosis. For this study, there will be no distinction made between participants who have been diagnosed with AD and those who show signs of MCI. ClinicalTrials.gov registry number: NCT03883633

If you or someone you love might be interested in participating in the study, there are three locations to choose from: Ashland, Oregon headed up by Deborah Gordon MD; San Francisco East Bay headed up by Kat Toups MD; and San Francisco North Bay headed up by Ann Hathaway MD.